Janus Henderson Group PLC Has $23 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Janus Henderson Group PLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 56.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 69,207 shares of the company's stock after purchasing an additional 25,089 shares during the period. Janus Henderson Group PLC owned about 0.22% of Medpace worth $23,002,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MEDP. R Squared Ltd bought a new position in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace during the 4th quarter valued at about $31,000. Jones Financial Companies Lllp grew its position in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC raised its holdings in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the period. Finally, Assetmark Inc. raised its holdings in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the period. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of research analyst reports. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Truist Financial dropped their target price on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday, April 23rd. Robert W. Baird reduced their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and lowered their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. Finally, William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $349.30.

Medpace Stock Performance

Medpace stock traded up $0.32 during midday trading on Monday, reaching $305.98. 188,958 shares of the company's stock were exchanged, compared to its average volume of 350,640. The stock's 50-day simple moving average is $304.24 and its 200 day simple moving average is $327.86. The firm has a market cap of $8.79 billion, a price-to-earnings ratio of 24.23, a P/E/G ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period in the previous year, the company posted $3.20 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.30% of the stock is currently owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.